Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.74 +0.28 (+1.60%)
Official Closing Price Updated: 7:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,871,591
Open 17.55
Bid (Size) 17.75 (1)
Ask (Size) 17.80 (8)
Prev. Close 17.46
Today's Range 17.34 - 17.78
52wk Range 8.055 - 19.08
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire

Performance

YTD
+66.26%
+66.26%
1 Month
-4.62%
-4.62%
3 Month
+9.17%
+9.17%
6 Month
+22.94%
+22.94%
1 Year
+73.58%
+73.58%

More News

Read More
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
Via Benzinga
Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
Via Benzinga
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva to Present at the Bank of America 2024 Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
Via Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Via Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Via Benzinga
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Via Benzinga
The 7 Best Under $20 Stocks to Buy in August 2024
Via InvestorPlace
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Via InvestorPlace
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.